Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Bayer Secured The Top-Spot In China: An Interview With Liam Condon

This article was originally published in PharmAsia News

Executive Summary

With China set to become the third largest pharmaceutical market in the world by 2011, and the second largest OTC market next year, Bayer Schering Pharma AG is well-positioned to benefit. Larger in China than most of its Western counterparts, with over $750 million in 2008 sales, accounting for an unusually high 4.8% of global health care revenues, Bayer has understood and adapted to the fundamental differences between the Chinese market and those closer to home
Advertisement

Related Content

On Heels Of U.S. Approval, BMS, Pfizer Launch Eliquis Ahead Of Pradaxa In China
On Heels Of U.S. Approval, BMS, Pfizer Launch Eliquis Ahead Of Pradaxa In China
Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
Market Rumors Grow On Potential GSK Purchase Of Nanjing MeiRui Pharma For Urology Expansion In China
Bayer Shifting Further To Emerging Markets Including China
Bayer Schering Forges Women's Health Research Partnership With Beijing's People's Liberation Army General Hospital
With Spotlight On China, Regional Asian Opportunities Are Also Bright
Beyond BRIC: 'Pharmerging' Markets Loom If Pharma Is To Expand -IMS Study
China's Health Reform Will Nurture New Drugs, While Boosting Use Of Old Ones - PharmAsia Summit
China's Health Reform Will Nurture New Drugs, While Boosting Use Of Old Ones - PharmAsia Summit
Advertisement
UsernamePublicRestriction

Register

SC074146

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel